Repository logo
 

Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trial.

Published version
Peer-reviewed

Change log

Authors

Ghimire, Bhagabati 
Landy, Rebecca 
Maroni, Roberta 
Smith, Samuel G 
Debiram-Beecham, Irene 

Abstract

BACKGROUND: The Cytosponge is a cell-collection device, which, coupled with a test for trefoil factor 3 (TFF3), can be used to diagnose Barrett's oesophagus, a precursor condition to oesophageal adenocarcinoma. BEST3, a large pragmatic, randomised, controlled trial, investigated whether offering the Cytosponge-TFF3 test would increase detection of Barrett's. Overall, participants reported mostly positive experiences. This study reports the factors associated with the least positive experience. METHODS: Patient experience was assessed using the Inventory to Assess Patient Satisfaction (IAPS), a 22-item questionnaire, completed 7-14 days after the Cytosponge test. STUDY COHORT: All BEST3 participants who answered ≥ 15 items of the IAPS (N = 1458). STATISTICAL ANALYSIS: A mean IAPS score between 1 and 5 (5 indicates most negative experience) was calculated for each individual. 'Least positive' experience was defined according to the 90th percentile. 167 (11.4%) individuals with a mean IAPS score of ≥ 2.32 were included in the 'least positive' category and compared with the rest of the cohort. Eleven patient characteristics and one procedure-specific factor were assessed as potential predictors of the least positive experience. Multivariable logistic regression analysis using backwards selection was conducted to identify factors independently associated with the least positive experience and with failed swallow at first attempt, one of the strongest predictors of least positive experience. RESULTS: The majority of responders had a positive experience, with an overall median IAPS score of 1.7 (IQR 1.5-2.1). High (OR = 3.01, 95% CI 2.03-4.46, p < 0.001) or very high (OR = 4.56, 95% CI 2.71-7.66, p < 0.001) anxiety (relative to low/normal anxiety) and a failed swallow at the first attempt (OR = 3.37, 95% CI 2.14-5.30, p < 0.001) were highly significant predictors of the least positive patient experience in multivariable analyses. Additionally, sex (p = 0.036), height (p = 0.032), alcohol intake (p = 0.011) and education level (p = 0.036) were identified as statistically significant predictors. CONCLUSION: We have identified factors which predict patient experience. Identifying anxiety ahead of the procedure and discussing particular concerns with patients or giving them tips to help with swallowing the capsule might help improve their experience. Trial registration ISRCTN68382401.

Description

Funder: National Institutes of Health; doi: http://dx.doi.org/10.13039/100000002


Funder: Yorkshire Cancer Research; doi: http://dx.doi.org/10.13039/501100002653

Keywords

Barrett’s oesophagus, Cytosponge, Inventory to assess patient satisfaction, Patient experience, Humans, Adenocarcinoma, Barrett Esophagus, Deglutition, Esophageal Neoplasms, Patient Satisfaction

Journal Title

BMC Gastroenterol

Conference Name

Journal ISSN

1471-230X
1471-230X

Volume Title

Publisher

Springer Science and Business Media LLC
Sponsorship
Innovate UK (105857, 105857, 105857)
Cancer Research UK (C14478/A21047, C8162/A16892, C8162/A25356, C7492/A17219, C8640/A23385, C14478/A21047, C8162/A16892, C8162/A25356, C7492/A17219, C8640/A23385, C14478/A21047, C8162/A16892, C8162/A25356, C7492/A17219, C8640/A23385, C14478/A21047, C8162/A16892, C8162/A25356, C7492/A17219, C8640/A23385, C14478/A21047, C8162/A16892, C8162/A25356, C7492/A17219, C8640/A23385, C14478/A21047, C8162/A16892, C8162/A25356, C7492/A17219, C8640/A23385, C14478/A21047, C8162/A16892, C8162/A25356, C7492/A17219, C8640/A23385)
Medical Research Council (RG84369)